Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

International Biotechnology Trust (IBT) Ordinary 25p Shares

Sell:754.00p Buy:762.00p 0 Change: 6.00p (0.79%)
Market closed Prices as at close on 4 June 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:754.00p
Buy:762.00p
Change: 6.00p (0.79%)
Market closed Prices as at close on 4 June 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:754.00p
Buy:762.00p
Change: 6.00p (0.79%)
Market closed Prices as at close on 4 June 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Objective

The objective is to achieve long term capital growth by investing in high growth, development stage biotechnology companies that are either quoted or unquoted. The company invests in companies that are considered to be good value with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
Security Weight
Vertex Pharmaceuticals Inc 6.30%
Gilead Sciences Inc 6.03%
Biogen Inc 4.92%
Biomarin Pharmaceutical Inc 4.88%
ACADIA Pharmaceuticals Inc 4.84%
Amgen Inc 4.55%
PTC Therapeutics Inc 4.07%
Horizon Therapeutics plc Ordinary Shares 3.97%
Genmab A/S DKK1 3.41%
Neurocrine Biosciences Inc 3.16%
Sector Weight
Healthcare 85.40%
Country Weight
United States 72.54%
Denmark 6.16%
Switzerland 2.66%
Germany 1.40%
Netherlands 1.36%
China 0.53%
Ireland 0.43%
United Kingdom 0.30%

Fee Structure

Management fee payable monthly at the rate of 0.9% p.a. of the NAV. The performance fee on the unquoted pool is 20% of net realised gain performance fee on the quoted pool is 10% of relative outperformance above the sterling-adjusted NBI plus a 0.5% hurdle.

Dividend Policy

The Board introduces an annual dividend, equals to 4% of the last day NAV of the financial year. Dividends are paid to shareholders semi-annually on January and August each year.

ASSET SPLIT

Total number of holdings: 73.

Trust Manager

Carl Harald Janson

Manager Bio

Not currently available for this investment trust.

Board Of Directors

John AstonChairman, Katherine Cornish-Bowden, Veronique Bouchet, Jim Horsburgh, Caroline Gulliver, Patrick Magee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.